Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) adapted for use in adult patients: report from an initial validation study

Table 3 Construct validity of the Localized Scleroderma Cutaneous Assessment Tool components with global assessment of disease tools

	PhysGA-A		PtGA-S
	r_s (95% CI)	p	r_s (95% CI)	p
mLoSSI	0.64 (0.39, 0.79)	< 0.01	0.46 (0.16, 0.68)	< 0.01
New lesion / lesion extension (N/E)	0.68 (0.45, 0.81)	< 0.01	0.3 (−0.02, 0.56)	0.06
Erythema (ER)	0.53 (0.25, 0.72)	< 0.01	0.42 (0.11, 0.65)	< 0.01
Skin thickness (ST)	0.47 (0.18, 0.69)	< 0.01	0.39 (0.07, 0.62)	< 0.01
	PhysGA-D		PtGA-D
	r_s (95% CI)	p	r_s (95% CI)	p
LoSDI	0.47 (0.17, 0.68)	< 0.01	0.24 (−0.09, 0.51)	0.14
Dermal atrophy (DAT)	0.33 (0.01, 0.58)	0.04	0.29 (−0.03, 0.55)	0.07
Subcutaneous atrophy (SAT)	0.44 (0.14, 0.66)	< 0.01	0.18 (−0.15, 0.47)	0.27
Dyspigmentation (DP)	0.42 (0.10, 0.64)	< 0.01	0.1 (−0.22, 0.40)	0.54

CI confidence interval, mLoSSI modified Localized Scleroderma Skin Severity Index, PhysGA-A physician global assessment of disease activity, PtGA-S patient global assessment of disease severity, LoSDI Localized Scleroderma Damage Index, PhysGA-D physician global assessment of disease damage, PtGA-D patient global assessment of disease damage, r_s Spearman’s rank correlation coefficient, p p-value

ISSN: 1477-7525